| Name | Title | Contact Details |
|---|
UCLA offers a combination thats rare, especially among public research universities. The breadth, depth and inspired excellence among academic programs—from the visual and performing arts to the humanities, social sciences, STEM disciplines and health sciences—add up to endless opportunity. The location is unmatched: a campus that is unexpectedly picturesque and compact, set in a thriving and diverse global city.
Skye Bioscience Inc. is a clinical-stage biotechnology company based in San Diego, California. The company focuses on developing innovative therapeutics for metabolic diseases, particularly obesity, by modulating the endocannabinoid system. Skye Bioscience is advancing its lead product, Nimacimab, a monoclonal antibody that targets peripheral CB1 receptors. This treatment aims to provide effective weight loss solutions while minimizing neuropsychiatric side effects associated with previous therapies. Nimacimab is currently in a Phase 2 trial, evaluating its efficacy in weight loss and metabolic health. The company is also exploring combination therapies to enhance treatment outcomes. Skye Bioscience positions Nimacimab as a potential alternative to existing GLP-1-based therapies, targeting patients who need sustainable weight loss with improved safety profiles. The obesity drug market presents significant opportunities, and Skye is actively participating in clinical trials and industry conferences to advance its mission in metabolic health.
Totalis Consulting Group is a Alpharetta, GA-based company in the Business Services sector.
Chrysalis is a New York, NY-based company in the Business Services sector.
Hera Diagnostics integrates innovative technologies to deliver revolutionary disease diagnostic tools